Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2264 - Analysis of efficacy and prognostic factors for second-line chemotherapy in gemcitabine-refractory advanced biliary tract cancer


08 Oct 2016


Poster Display


Naohiro Okano


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


N. Okano, K. Kawai, T. Kobayashi, D. Naruge, F. Nagashima, J. Furuse

Author affiliations

  • Medical Oncology, Kyorin university Hospital, 181-8611 - Mitaka/JP


Abstract 2264


No standard second-line chemotherapy regimen has been established for gemcitabine (GEM)-refractory advanced biliary tract cancer (aBTC).


We examined the transition rate to second-line chemotherapy and its safety and efficacy in patients with aBTC who had received first-line treatment with GEM-based chemotherapy between January 2009 and December 2015 in our hospital. We also investigated prognostic factors associated with overall survival (OS) by multivariable Cox regression analysis.


Forty-six (45.1%) patients received second-line chemotherapy. One patient was excluded from this study, because second-line treatment was initiated in another hospital. The median age was 68 years, and there were 25 males and 20 females. Tumor sites were: gallbladder (n = 18), extrahepatic (n = 15), intrahepatic (n = 10) bile duct and ampulla of Vater (n = 2). Performance status was 0 and 1 in 25 and 20 patients, respectively. Cancer was metastatic in 27, recurrent in 15, and locally advanced in 3. Median CA 19-9 value was 487 U/mL. Modified Glasgow prognostic score (mGPS) were: 0 (n = 24), 1 (n = 10), and 2 (n = 10). First-line chemotherapy were included: GEM + cisplatin (CDDP) (n = 19), GEM + S-1 (n = 14), GEM (n = 7), GEM + OTS102 (n = 4), and GEM + radiation (n = 1). Second-line chemotherapy included: S-1 (n = 20), GEM + oxaliplatin (n = 6), GEM + CDDP (n = 5), GEM (n = 5), tyrosine kinase inhibitors (n = 5), GEM + S-1 (n = 2), and fixed-dose GEM + S-1 (n = 2). The main grade 3/4 adverse events were biliary tract infection (n = 6), neutropenia (n = 5), and anemia (n = 5). There was one treatment-related death due to biliary tract infection. Median OS was 8.3 months, and median progression-free survival was 3.0 months. Response rate was 0% and disease control rate was 58.1%. Multivariate analysis showed that CA 19-9 ≥500 U/mL (hazard ratio: [HR] 3.45, p = 0.003), mGPS ≥1 (HR 3.05, p = 0.005), and liver metastasis (HR 2.62, p = 0.048) were significant prognostic factors for OS.


Second-line chemotherapy for GEM-refractory aBTC was inadequate. Randomized controlled trials with an appropriate stratification criteria, including CA 19-9 value, mGPS and liver metastasis, are required.

Clinical trial identification

Legal entity responsible for the study

Kyorin University


Kyorin University


J. Furuse: Personal financial interests from Taiho Pharmaceutical Co., Ltd, and Eli Lilly Japan. Institutional financial interests from Taiho Pharmaceutical Co., Ltd.

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings